255
Participants
Start Date
October 31, 2004
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
levetiracetam (LEV)
Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
Mobile
Phoenix
Los Angeles
Denver
Washington D.C.
Bradenton
Loxahatchee Groves
Orlando
Pensacola
Tallahassee
Tampa
Atlanta
Augusta
Chicago
New Orleans
Boston
Saint Paul
Lebanon
Edison
Voorhees Township
Buffalo
New York
Rochester
Syracuse
Chapel Hill
Cleveland
Hershey
Philadelphia
Charleston
Germantown
Nashville
Fort Worth
Galveston
Salt Lake City
Norfolk
Richmond
Morgantown
Milwaukee
Brussels
Leuven
Campinas
Curitiba
Porto Alegre
Ribeirão Preto
Rio de Janeiro
São Paulo
Vancouver
Thornhill
Toronto
Brno
Prague
Lille
Paris
Strasbourg
Kehl
Berlin
Erlangen
Heidelberg
Jena
Kiel
Budapest
Hyderabad
Lucknow
Mahim Mumbai
Mumbai
Pune Maharashtra
Calambrone
Genoa
Milan
Roma
Mexico City
Gdansk
Bucharest
Cluj-Napoca
Târgu Mureş
Kalingrad
Moscow
Saint Petersburg
Cape Town
Capitol Park
Johannesburg
Bristol
Cardiff
London
Lead Sponsor
UCB Pharma
INDUSTRY